Back to top

Analyst Blog

Zacks Equity Research

Cubist Pharma Buys Adolor

CBST

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Cubist Pharmaceuticals Inc. (CBST - Analyst Report) expanded its portfolio by completing the purchase of biopharmaceutical company Adolor Corporation at $4.25 per share as an upfront cash payment ($221 million).

Moreover, shareholders of Adolor are eligible to receive a contingent payment right per share. This provision makes the shareholder eligible for additional cash payments from Cubist Pharma of up to $4.50 per share in the event of chronic opioid induced constipation candidate ADL5945 achieving certain milestones. The deal was announced in October 2011.

As a result of the completion of the deal, Cubist Pharma gets access to Entereg (alvimopan). The drug is marketed in the US to expedite the time needed for upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis.

The addition of Entereg to the portfolio will bring in additional revenues for Cubist Pharma. Prior to the acquisition, Cubist Pharma had two products in its product portfolio, Cubicin and Dificid.

Cubist Pharma’s primary growth driver is its antibiotic injection, Cubicin (daptomycin). Cubicin is marketed in the US and several other markets for the treatment of severe bacterial infections of the skin and bloodstream.

Another marketed product at Cubist Pharma is Dificid (fidaxomicin) for treating patients suffering from clostridium difficile-associated diarrhea. Cubist Pharma has a two-year agreement with Optimer Pharmaceuticals Inc. for the co-promotion of Dificid in the US. We note that Optimer has developed Dificid.

Our Recommendation

Even though we are positive on the purchase of Adolor, we prefer to remain on the sidelines until the benefits of the acquisition start flowing in at Cubist Pharma. Consequently, we have a Neutral recommendation on Cubist Pharma which is in line with the Zacks #3 Rank (Hold rating) carried by the stock in the short-run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.33 +14.82%
ANI PHARMACE ANIP 24.79 +14.66%
E HOUSECHINA EJ 10.99 +9.24%
CANADIAN SOL CSIQ 26.97 +7.15%
INTERNATIONA ICAGY 33.30 +5.38%